1-155610313-C-A
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3PP5
The NM_018116.4(MSTO1):c.65C>A(p.Ala22Glu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (no stars).
Frequency
Consequence
NM_018116.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 26
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 912646Hom.: 0 Cov.: 12 AF XY: 0.00 AC XY: 0AN XY: 457514
GnomAD4 genome Cov.: 26
ClinVar
Submissions by phenotype
See cases Pathogenic:1
The c.65C>A (p.22AlaGlu) variant in MSTO1 is absent from large population studies. It has been identified in compound heterozygosity with the c.220+5 splice variant (induces exon skipping; nonsense-mediated mRNA decay highly suspected from mRNA analysis in patient cells) in three siblings affected with typical MSTO1-associated myopathy, cerebellar atrophy and corticospinal involvement associated with a previously unreported optic neuropathy responsible for a profound central visual loss. Biallelism has been experimentally demonstrated. Multiple line of computational evidence support deleterious effect of the variant. In summary, the variant meets criteria to be classified as likely pathogenic based upon phenotype, family history, segregation studies, absence from controls and computational predictions. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.